| Title | Management of rheumatoid arthritis. |
| Author(s) | Handa R |
| Institution | Clinical Immunology and Rheumatology Service, Department of Medicine, All India Institute of Medical Sciences, New Delhi 110029, India. rohinihanda@hotmail.com |
| Source | Natl Med J India 2004 May-Jun; 17(3):143-51. |
| MeSH | Adrenal Cortex Hormones
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Arthritis, Rheumatoid
Biological Response Modifiers
Humans
Tumor Necrosis Factor-alpha
|
| Abstract | The past few years have witnessed a major change in the approach to the treatment of rheumatoid arthritis. The present focus is on early recognition and prompt treatment with disease-modifying antirheumatic drugs of which methotrexate continues to be the drug of choice. Leflunomide is an important recent addition to the list of available drugs. The use of combinations of disease-modifying antirheumatic drugs is gaining wide acceptance. A better understanding of the pathobiology of rheumatoid arthritis has led to the development of targeted therapies such as tumour necrosis factor blockers. There are robust data to show the clinical utility of tumour necrosis factor blockers in patients with rheumatoid arthritis. |
| Language | eng |
| Pub Type(s) | Journal Article
Review
|
| PubMed ID | 15253402 |
